Next generation human microbiome therapeutics.
The human microbiome has emerged as a key driver of immune dysfunction. At Siolta Therapeutics, we leverage multi-scale next-generation microbiome analyses to develop and test microbial-based therapeutics for induction and maintenance of immune tolerance.
Microbial seeds for human microbiome management.
At Siolta Therapeutics, we harness information from human microbiome studies to design next-generation microbial therapeutics that re-engineer the human microbiome to prevent or reduce inflammatory processes.
“Understanding and leveraging the microbiome to influence human health, represents one of the most exciting areas of therapeutic development in the modern era.”Susan Lynch – Founder | Board Member
Our research focuses on microbial communities associated with chronic inflammatory diseases of the gastrointestinal and respiratory tracts. Using clinical samples to inform studies using murine models, we examine relationships between microbial community composition and function in an effort to better understand microbial-host interplay in the context of chronic inflammatory disease.